SEC Form 4 · accession 0001209191-15-022578
Anacor Pharmaceuticals, Inc. · ANAC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sanjay Chanda
Officer — SVP, Drug Development
Period of report
Mar 4, 2015
Accepted (ET)
Mar 4, 2015 · 7:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 4, 2015 | M | 4,952 | $7.25 | A | 34,039 | D | |
| Common Stock | Mar 4, 2015 | S | 4,952 | $45.00 | D | 29,087 | D | |
| Common Stock | Mar 4, 2015 | M | 48 | $7.55 | A | 29,135 | D | |
| Common Stock | Mar 4, 2015 | S | 48 | $45.00 | D | 29,087 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $7.25 | Mar 4, 2015 | M | 4,952 | D | — | Mar 26, 2018 | Common Stock | 4,952 | 0 | D |
| Stock Option (right to buy)F2 | $7.55 | Mar 4, 2015 | M | 48 | D | — | Aug 20, 2020 | Common Stock | 48 | 13,552 | D |
Explanation of responses
- F1This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- F2This option is fully vested and exercisable.